跳至主要内容
临床试验/NCT05096988
NCT05096988已完成不适用

A Study to Evaluate the Acceptability, Tolerance and Adherence of Children and Adults Consuming PKU Sphere Liquid, a Food for Special Medical Purposes (FSMP), for the Dietary Management of Phenylketonuria (PKU)

Vitaflo International, Ltd6 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2021年11月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
19
试验地点
6
主要终点
Questionnaire of self-reported adherence to the prescribed amount of study product

研究概览

简要总结

PKU Sphere Liquid is a prospective, open-label, acceptability study to evaluate PKU sphere liquid in up to 15 participants aged 3 and above for the dietary management of PKU over 31 days.

详细描述

PKU Sphere Liquid is a newly-developed Food for Special Medical Purposes (FSMP) designed for the dietary management of patients with phenylketonuria (PKU).

PKU sphere liquid is a vanilla flavoured, ready-to-drink, low phenylalanine protein substitute containing a blend of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and Docosachexaenoic acid (DHA).

This is a feasibility study designed to evaluate the acceptability, tolerance and adherence of children and adults consuming PKU sphere liquid.

Participants will be given a four-week supply of PKU Sphere Liquid and they will be asked to complete a daily diary and short questionnaire for four weeks to record information on: adherence, gastrointestinal tolerance, palatability and how the product is used.

Each participant will be on the trial for 31 days. This includes a 3-day baseline period and 28 days taking the study product. If deemed appropriate in each individual circumstance, the sponsor of the trial, Vitaflo International Ltd, will continue to supply the product free of charge at the end of the trial until available on prescription.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of PKU requiring a low protein diet and protein substitute.
  • Aged three (3) years and over
  • Already taking a minimum of one GMP based protein substitute per day or have previously taken one
  • Able to comply with the study protocol and take the study product, according to the opinion of the PI.
  • Willingly given, written, informed consent from patient or parent/guardian.
  • Willingly given, written assent (if appropriate).

排除标准

  • Inability to comply with the study protocol, in the opinion of the investigator.
  • Any co-morbidity, which, in the opinion of the investigator, would preclude participation in the study.
  • Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and protein supplement.
  • Unwilling/unable to take a GMP based protein substitute.
  • Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period.
  • N.B.: Women who become pregnant unexpectedly during this study will be immediately withdrawn from the study.

结局指标

主要结局

Questionnaire of self-reported adherence to the prescribed amount of study product

时间窗: 4 weeks

Assessment of participant's adherence to prescribed amount during the eight week intake of the study product

Questionnaire of self-reported changes in gastrointestinal tolerance during four week intake

时间窗: 4 weeks

Assessment of participant's gastrointestinal tolerance during the four week intake of the study product

Product acceptability rated on a Likert scale by the participant after four week intake

时间窗: 4 weeks

Assessment of participant's acceptability following four week intake of the study product Scale is from 1 to 5: 1 = Loved it, 5 = Really didn't like it

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验